CD98 at the crossroads of adaptive immunity and cancer

Joseph M. Cantor; Mark H. Ginsberg

doi:10.1242/jcs.096040

journal article Jan 01, 2012

CD98 at the crossroads of adaptive immunity and cancer

Joseph M. Cantor Mark H. Ginsberg

Journal of Cell Science · The Company of Biologists

View at Publisher Save 10.1242/jcs.096040

Abstract

Adaptive immunity, a vertebrate specialization, adds memory and exquisite specificity to the basic innate immune responses present in invertebrates while conserving metabolic resources. In adaptive immunity, antigenic challenge requires extremely rapid proliferation of rare antigen-specific lymphocytes to produce large, clonally expanded effector populations that neutralize pathogens. Rapid proliferation and resulting clonal expansion are dependent on CD98, a protein whose well-conserved orthologs appear restricted to vertebrates. Thus, CD98 supports lymphocyte clonal expansion to enable protective adaptive immunity, an advantage that could account for the presence of CD98 in vertebrates. CD98 supports lymphocyte clonal expansion by amplifying integrin signals that enable proliferation and prevent apoptosis. These integrin-dependent signals can also provoke cancer development and invasion, anchorage-independence and the rapid proliferation of tumor cells. CD98 is highly expressed in many cancers and contributes to formation of tumors in experimental models. Strikingly, vertebrates, which possess highly conserved CD98 proteins, CD98-binding integrins and adaptive immunity, also display propensity towards invasive and metastatic tumors. In this Commentary, we review the roles of CD98 in lymphocyte biology and cancer. We suggest that the CD98 amplification of integrin signaling in adaptive immunity provides survival benefits to vertebrates, which, in turn, bear the price of increased susceptibility to cancer.

Topics

No keywords indexed for this article. Browse by subject →

References

129

[1]

Abbas (2003)

[2]

Allen "Imaging of germinal center selection events during affinity maturation" Science (2007) 10.1126/science.1136736

[3]

Assoian "Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression" Curr. Opin. Genet. Dev. (2001) 10.1016/s0959-437x(00)00155-6

[4]

Bertran "Stimulation of system y(+)-like amino acid transport by the heavy chain of human 4F2 surface antigen in Xenopus laevis oocytes" Proc. Natl. Acad. Sci. USA (1992) 10.1073/pnas.89.12.5606

[5]

Boehm "Design principles of adaptive immune systems" Nat. Rev. Immunol. (2011) 10.1038/nri2944

[6]

Bron "Structural homology between the human 4F2 antigen and a murine cell surface glycoprotein associated with lymphocyte activation" J. Immunol. (1986) 10.4049/jimmunol.137.2.397

[7]

Cai "CD98 modulates integrin beta1 function in polarized epithelial cells" J. Cell Sci. (2005) 10.1242/jcs.01674

[8]

Campbell "TA1/LAT-1/CD98 light chain and system L activity, but not 4F2/CD98 heavy chain, respond to arginine availability in rat hepatic cells. Loss of response in tumor cells" J. Biol. Chem. (2000) 10.1074/jbc.275.8.5347

[9]

Cantor "CD98hc facilitates B cell proliferation and adaptive humoral immunity" Nat. Immunol. (2009) 10.1038/ni.1712

[10]

Cantor "Loss of T cell CD98 H chain specifically ablates T cell clonal expansion and protects from autoimmunity" J. Immunol. (2011) 10.4049/jimmunol.1100002

[11]

Glutamine Uptake and Metabolism Are Coordinately Regulated by ERK/MAPK during T Lymphocyte Activation

Erikka L Carr, Alina Kelman, Glendon S Wu et al.

The Journal of Immunology 2010 10.4049/jimmunol.0903586

[12]

Chang "Asymmetric T lymphocyte division in the initiation of adaptive immune responses" Science (2007) 10.1126/science.1139393

[13]

Cho "The functional interactions between CD98, beta1-integrins, and CD147 in the induction of U937 homotypic aggregation" Blood (2001) 10.1182/blood.v98.2.374

[14]

Cho "Cynaropicrin, a sesquiterpene lactone, as a new strong regulator of CD29 and CD98 functions" Biochem. Biophys. Res. Commun. (2004) 10.1016/j.bbrc.2003.12.026

[15]

Integrins in cancer: biological implications and therapeutic opportunities

Jay S. Desgrosellier, David A. Cheresh

Nature Reviews Cancer 2010 10.1038/nrc2748

[16]

Deves "Surface antigen CD98(4F2): not a single membrane protein, but a family of proteins with multiple functions" J. Membr. Biol. (2000) 10.1007/s002320001017

[17]

Diaz "Monocyte-dependent regulation of T lymphocyte activation through CD98" Int. Immunol. (1997) 10.1093/intimm/9.9.1221

[18]

Esseghir "Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts" J. Pathol. (2006) 10.1002/path.2071

[19]

Esteban "Relationship of 4F2 antigen with local growth and metastatic potential of squamous cell carcinoma of the larynx" Cancer (1990) 10.1002/1097-0142(19901001)66:7<1493::aid-cncr2820660710>3.0.co;2-0

[20]

Fenczik "Complementation of dominant suppression implicates CD98 in integrin activation" Nature (1997) 10.1038/36349

[21]

Fenczik "Distinct domains of CD98hc regulate integrins and amino acid transport" J. Biol. Chem. (2001) 10.1074/jbc.m011239200

[22]

Feral "CD98hc (SLC3A2) mediates integrin signaling" Proc. Natl. Acad. Sci. USA (2005) 10.1073/pnas.0404852102

[23]

Feral "CD98hc (SLC3A2) participates in fibronectin matrix assembly by mediating integrin signaling" J. Cell Biol. (2007) 10.1083/jcb.200705090

[24]

Fernandez-Herrera "Differential expression of the 4F2 activation antigen on human follicular epithelium in hair cycle" J. Invest. Dermatol. (1989) 10.1111/1523-1747.ep12276789

[25]

Fogelstrand "Dependence of proliferative vascular smooth muscle cells on CD98hc (4F2hc, SLC3A2)" J. Exp. Med. (2009) 10.1084/jem.20082845

[26]

Fort "The structure of human 4F2hc ectodomain provides a model for homodimerization and electrostatic interaction with plasma membrane" J. Biol. Chem. (2007) 10.1074/jbc.m704524200

[27]

Freidman "The human 4F2 antigen: evidence for cryptic and noncryptic epitopes and for a role of 4F2 in human T lymphocyte activation" Cell Immunol. (1994) 10.1006/cimm.1994.1075

[28]

Gavin "Dual TCR T cells: gaining entry into the periphery" Nat. Immunol. (2002) 10.1038/ni0202-109

[29]

Gerrard "Modulation of human B cell responses by a monoclonal antibody to an activation antigen 4F2" Clin. Exp. Immunol. (1984)

[30]

Gottesdiener "Isolation and structural characterization of the human 4F2 heavy-chain gene, an inducible gene involved in T-lymphocyte activation" Mol. Cell. Biol. (1988) 10.1128/mcb.8.9.3809

[31]

Hafler "Investigation of in vivo activated T cells in multiple sclerosis and inflammatory central nervous system diseases" Clin. Immunol. Immunopathol. (1985) 10.1016/0090-1229(85)90147-3

[32]

Hara "Malignant transformation of NIH3T3 cells by overexpression of early lymphocyte activation antigen CD98" Biochem. Biophys. Res. Commun. (1999) 10.1006/bbrc.1999.1051

[33]

Harburger "Integrin signalling at a glance" J. Cell Sci. (2009) 10.1242/jcs.018093

[34]

Haynes "Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides" J. Clin. Invest. (1981) 10.1172/jci110062

[35]

Haynes "Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes" J. Immunol. (1981) 10.4049/jimmunol.126.4.1409

[36]

Hemler "Characterization of antigen recognized by the monoclonal antibody (4F2): different molecular forms on human T and B lymphoblastoid cell lines" J. Immunol. (1982) 10.4049/jimmunol.129.2.623

[37]

Henderson "CD98hc (SLC3A2) interaction with beta 1 integrins is required for transformation" J. Biol. Chem. (2004) 10.1074/jbc.m408700200

[38]

Herrin "Alternative adaptive immunity in jawless vertebrates" J. Immunol. (2010) 10.4049/jimmunol.0903128

[39]

Hildeman "Apoptosis and the homeostatic control of immune responses" Curr. Opin. Immunol. (2007) 10.1016/j.coi.2007.05.005

[40]

Holte "The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas" Int. J. Cancer (1987) 10.1002/ijc.2910390508

[41]

Holte "Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma" Int. J. Cancer (1989) 10.1002/ijc.2910440605

[42]

Hsu "V(D)J recombination: of mice and sharks" Adv. Exp. Med. Biol. (2009) 10.1007/978-1-4419-0296-2_14

[43]

Huck "beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression" Proc. Natl. Acad. Sci. USA (2010) 10.1073/pnas.1003034107

[44]

Imai "Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer" Anticancer Res. (2010)

[45]

Kaira "l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms" Cancer Sci. (2008) 10.1111/j.1349-7006.2008.00969.x

[46]

Kaira "Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors" Oncol. Rep. (2009)

[47]

Kaira "Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma" Lung Cancer (2009) 10.1016/j.lungcan.2008.12.015

[48]

Kaira "CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases" Ann. Surg. Oncol. (2009) 10.1245/s10434-009-0685-0

[49]

Kaira "Evaluation of thoracic tumors with (18)F-FMT and (18)F-FDG PET-CT: a clinicopathological study" Int. J. Cancer (2009) 10.1002/ijc.24034

[50]

Kehrl "Differential expression of cell activation markers after stimulation of resting human B lymphocytes" J. Immunol. (1984) 10.4049/jimmunol.132.6.2857

Showing 50 of 129 references

Metrics

109

Citations

129

References

Details

Published: Jan 01, 2012

Authors

Cite This Article

Joseph M. Cantor, Mark H. Ginsberg (2012). CD98 at the crossroads of adaptive immunity and cancer. Journal of Cell Science. https://doi.org/10.1242/jcs.096040

CD98 at the crossroads of adaptive immunity and cancer

You May Also Like